First Relief is a wearable PENS device that is placed behind the ear.
All articles by Brian Park, PharmD
PLG0206 is an investigational, broad-spectrum, anti-biofilm, anti-infective peptide therapeutic.
The expanded approval was based on data from the phase 4 MIRROR trial, which evaluated Krystexxa plus methotrexate in 152 adults with uncontrolled gout.
RoxyBond is an abuse-deterrent formulation of immediate-release oxycodone that features a unique abuse-deterrent technology.
Patients prescribed the 30 mg dose who receive the 60 mg dose may potentially be at risk for overdose and death.
Pharmacodynamic studies have shown that nalmefene has a longer duration of action than naloxone.
Eplontersen is an investigational ligand-conjugated antisense medicine designed to reduce the production of TTR protein to treat both hereditary and nonhereditary forms of ATTR.
The study evaluated Paxlovid in both vaccinated and unvaccinated patients with COVID-19 at standard risk for progressing to severe disease.
VLX-1005 is a first-in-class, selective small molecule inhibitor of 12-lipoxygenase, a key target within the arachidonic acid pathway.
Amvuttra is a subcutaneously-administered RNAi therapeutic designed to block the production of wild-type and mutant transthyretin protein.
Latest News Your top articles for SaturdayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses